Merrimack Pharmaceuticals Inc. (MACK) Initiates Phase 1 Clinical Study Of MM-398 In Combination With Cyclophosphamide For Pediatric Solid Tumors
1/23/2014 9:37:34 AM
CAMBRIDGE, Mass., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 dose-escalating clinical study of MM-398 in conjunction with cyclophosphamide for the treatment of pediatric solid tumors. MM-398 is a stable nanoliposomal irinotecan that is designed to exploit leaky tumor vasculature for enhanced drug delivery to tumors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by